|
| Category | Funding IC | Project Number | Sub Project # | Project Title | PI Name | Org Name | State / Country | Amount |
|
Ovarian Cancer
|
NCI
|
5K08CA106597-03
|
|
Chromatin structure and BRCA1 Checkpoint Function
|
GREENBERG, ROGER
|
UNIVERSITY OF PENNSYLVANIA
|
PA
|
$135,677
|
|
Ovarian Cancer
|
NCI
|
5R01CA119200-02
|
|
Optical Imaging of Ovarian Carcinogenesis in a Rat Menopause Model
|
BARTON, JENNIFER
|
UNIVERSITY OF ARIZONA
|
AZ
|
$282,857
|
|
Ovarian Cancer
|
NCI
|
5R37CA034992-26
|
|
CHEMISTRY AND BIOLOGY OF PLATINUM ANTICANCER DRUGS
|
LIPPARD, STEPHEN
|
MASSACHUSETTS INSTITUTE OF TECHNOLOGY
|
MA
|
$672,247
|
|
Ovarian Cancer
|
NCI
|
5R21CA125227-02
|
|
Microvascular Perfusion Sonographic Imaging to Detect Early Stage Ovarian Cancer
|
FISHMAN, DAVID
|
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
|
NY
|
$164,859
|
|
Ovarian Cancer
|
NIGMS
|
5R01GM073823-03
|
|
Functions for Myosin VI in the kidney proximal tubule
|
MOOSEKER, MARK
|
YALE UNIVERSITY
|
CT
|
$324,848
|
|
Ovarian Cancer
|
NCI
|
5R21CA116525-02
|
|
Design of targeted native tropism-ablated adenovirus
|
DMITRIEV, IGOR
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
AL
|
$145,500
|
|
Ovarian Cancer
|
NCI
|
5R21CA115568-02
|
|
Design of targeted cell vehicles to ovarian carcinoma
|
PEREBOEVA, LARISA
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
AL
|
$174,600
|
|
Ovarian Cancer
|
NCI
|
5R01CA120409-03
|
|
Immunotherapy of mesothelin expressing tumors with lentiviral engineered T cells
|
JUNE, CARL
|
UNIVERSITY OF PENNSYLVANIA
|
PA
|
$266,186
|
|
Ovarian Cancer
|
NCI
|
5R01CA079756-08
|
|
P53-Mediated G1/M Checkpoint Controls Altered by PPM1D
|
MERCER, W
|
THOMAS JEFFERSON UNIVERSITY
|
PA
|
$238,892
|
|
Ovarian Cancer
|
NCI
|
1R01CA131407-01
|
|
Re-activating Memory T Cells in the Microenvironment of Human Tumors
|
BANKERT, RICHARD
|
STATE UNIVERSITY OF NEW YORK AT BUFFALO
|
NY
|
$370,088
|
|
Ovarian Cancer
|
NCI
|
5R01CA101826-05
|
|
HOX genes in ovarian neoplasia
|
NAORA, HONAMI
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
TX
|
$234,808
|
|
Ovarian Cancer
|
NCI
|
5R01CA109619-04
|
|
Polyamine Catabolism in Platinum Drug Action
|
PENDYALA, LAKSHMI
|
ROSWELL PARK CANCER INSTITUTE CORP
|
NY
|
$297,716
|
|
Ovarian Cancer
|
NCI
|
5R01CA049449-19
|
|
Biochemical Markers in the nurses' Health Study Cohort
|
HANKINSON, SUSAN
|
BRIGHAM AND WOMEN'S HOSPITAL
|
MA
|
$1,213,763
|
|
Ovarian Cancer
|
NCI
|
2P01CA070970-10A1
|
0006
|
Cancer Stem Cells in Acute Lymphoblastic Leukemia and Ovarian Carcinoma
|
JONES, RICHARD
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$337,575
|
|
Ovarian Cancer
|
NCI
|
5R01CA111882-03
|
|
Regulation of Adhesion and Proteolysis in Ovarian Cancer
|
LENGYEL, ERNST
|
UNIVERSITY OF CHICAGO
|
IL
|
$264,562
|
|
Ovarian Cancer
|
NCI
|
5R01CA060651-16
|
|
Mouse Models to Study Gonadal Tumor Development
|
MATZUK, MARTIN
|
BAYLOR COLLEGE OF MEDICINE
|
TX
|
$265,968
|
|
Ovarian Cancer
|
NINR
|
1R21NR010571-01
|
|
The Feasibility of Earlier Detection of Ovarian Cancer Using Symptom Reports
|
ANDERSEN, M
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
WA
|
$224,927
|
|
Ovarian Cancer
|
NCI
|
5R01CA111914-04
|
|
Ovarian Cancer and Mismatch Repair Deficiency
|
PAL, TUYA
|
H. LEE MOFFITT CANCER CTR & RES INST
|
FL
|
$414,533
|
|
Ovarian Cancer
|
NCI
|
5R01CA039742-24
|
|
Epidemiology of Cancer in a Cohort of Older Women
|
FOLSOM, AARON
|
UNIVERSITY OF MINNESOTA TWIN CITIES
|
MN
|
$522,496
|
|
Ovarian Cancer
|
NCI
|
5R01CA104378-05
|
|
Therapeutic targeting of HSP90-dependent signaling
|
KARNITZ, LARRY
|
MAYO CLINIC COLL OF MEDICINE, ROCHESTER
|
MN
|
$258,036
|
|
Ovarian Cancer
|
NCI
|
5R01CA103920-05
|
|
BRCA1 and the Inactive X Chromosome
|
LIVINGSTON, DAVID
|
DANA-FARBER CANCER INSTITUTE
|
MA
|
$329,983
|
|
Ovarian Cancer
|
NCI
|
5U10CA013612-35
|
|
SOUTHWEST ONCOLOGY GROUP
|
MILLER, THOMAS
|
UNIVERSITY OF ARIZONA
|
AZ
|
$266,506
|
|
Ovarian Cancer
|
NCI
|
1R01CA132091-01
|
|
Targeted Nanoparticle DNA Therapy for Ovarian Cancer
|
SAWICKI, JANET
|
LANKENAU INSTITUTE FOR MEDICAL RESEARCH
|
PA
|
$304,559
|
|
Ovarian Cancer
|
NCI
|
1R01CA122728-01A2
|
|
Treatment of Chemotherapy-Resistant Human Ovarian Cancer by Administration of CPE
|
SANTIN, ALESSANDRO
|
YALE UNIVERSITY
|
CT
|
$346,272
|
|
Ovarian Cancer
|
NCI
|
1R01CA123233-01A2
|
|
Regulation of JNK-signaling molecules by the gep oncogenes
|
DHANASEKARAN, DANNY
|
TEMPLE UNIVERSITY
|
PA
|
$280,125
|
|
Ovarian Cancer
|
NIGMS
|
2R01GM052418-09
|
|
Mass Spectrometry Studies on Radical Reactions of DNA
|
KENTTAMAA, HILKKA
|
PURDUE UNIVERSITY WEST LAFAYETTE
|
IN
|
$216,530
|
|
Ovarian Cancer
|
NCI
|
1R01CA127239-01A1
|
|
pBACH1 binding site on BRCT(BRCA1): A novel approach to cancer therapeutics
|
NATARAJAN, AMARNATH
|
UNIVERSITY OF TEXAS MEDICAL BR GALVESTON
|
TX
|
$270,000
|
|
Ovarian Cancer
|
NCI
|
5R01CA114343-02
|
|
Haplotype-Based Genome Screen for Ovarian Cancer Loci
|
SELLERS, THOMAS
|
H. LEE MOFFITT CANCER CTR & RES INST
|
FL
|
$1,510,342
|
|
Ovarian Cancer
|
NCI
|
5R01CA109298-04
|
|
Ovarian Cancer: Mechanisms of Neuroendocrine Regulation
|
SOOD, ANIL
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
TX
|
$271,595
|
|
Ovarian Cancer
|
NCI
|
1R01CA123219-01A2
|
|
The Role of Aberrant Splicing of EVl1 in Ovarian Cancer Pathophysiology
|
MILLS, GORDON
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
TX
|
$327,989
|
|
Ovarian Cancer
|
NCI
|
5F31CA126474-02
|
|
Role of Src in Stress-Mediated Progression of Ovarian Cancer
|
ARMAIZ-PENA, GUILLERMO
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
TX
|
$38,115
|
|
Ovarian Cancer
|
NCI
|
5R01CA116674-03
|
|
Epigenetic regulation of cancer/germ-line antigen gene expression
|
KARPF, ADAM
|
ROSWELL PARK CANCER INSTITUTE CORP
|
NY
|
$275,878
|
|
Ovarian Cancer
|
NCI
|
1R44CA123785-01A2
|
|
Fast-Track:Biomagnetic In-vivo Imaging of Ovarian Cancer
|
FLYNN, EDWARD
|
SENIOR SCIENTIFIC
|
NM
|
$208,371
|
|
Ovarian Cancer
|
NCI
|
2R01CA103937-04
|
|
Molecular Diagnostics for Malignant Effusion
|
SHIH, IE-MING
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$338,148
|
|
Ovarian Cancer
|
NCI
|
5R01CA124630-02
|
|
PTTG Role in Ovarian Tumorigenesis and Matastasis
|
KAKAR, SHAM
|
UNIVERSITY OF LOUISVILLE
|
KY
|
$253,080
|
|
Ovarian Cancer
|
NCI
|
5R01CA106713-04
|
|
Mechanism of SHeA2 Action in Ovarian Cancer
|
BENBROOK, DORIS
|
UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR
|
OK
|
$272,533
|
|
Ovarian Cancer
|
NCI
|
5R01CA087660-09
|
|
Chemical Approaches for Activity Based Proteomics
|
CRAVATT, BENJAMIN
|
SCRIPPS RESEARCH INSTITUTE
|
CA
|
$323,425
|
|
Ovarian Cancer
|
NCI
|
5R01CA112291-04
|
|
BRIT 1: Roles in Immortalization, Checkpoints and Cancer
|
LIN, SHIAW-YIH
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
TX
|
$252,809
|
|
Ovarian Cancer
|
NCI
|
5R01CA103924-05
|
|
Molecular characterization of ovarian cancer in a mouse model
|
ORSULIC, SANDRA
|
MASSACHUSETTS GENERAL HOSPITAL
|
MA
|
$305,173
|
|
Ovarian Cancer
|
NCI
|
7R01CA079716-11
|
|
Ovarian Cancer: Epithelial Dedifferentiation
|
XU, XIANGXI
|
UNIVERSITY OF MIAMI SCHOOL OF MEDICINE
|
FL
|
$326,412
|
|
Ovarian Cancer
|
NCI
|
5R01CA051578-16
|
|
A POLYMERIC DRUG DELIVERY SYSTEM FOR CANCER THERAPY
|
KOPECEK, JINDRICH
|
UNIVERSITY OF UTAH
|
UT
|
$236,153
|
|
Ovarian Cancer
|
NCI
|
5R01CA111786-04
|
|
Novel Targets for Protection of T Cells From Tumor-Induced Dysfunction
|
RABINOWICH, HANNAH
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
PA
|
$268,039
|
|
Ovarian Cancer
|
NCI
|
5R01CA111334-04
|
|
Vitamin D and Ovarian Cancer Prevention and Treatment
|
BAI, WENLONG
|
UNIVERSITY OF SOUTH FLORIDA
|
FL
|
$244,382
|
|
Ovarian Cancer
|
NCI
|
5R01CA123197-02
|
|
Death Receptor-mediated Apoptosis and Therapy Strategies in Ovarian Cancer
|
ZHOU, TONG
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
AL
|
$439,913
|
|
Ovarian Cancer
|
NCI
|
5R01CA107195-04
|
|
Loss of Vitamin A Metabolism in Ovarian Oncogenesis
|
HAMILTON, THOMAS
|
FOX CHASE CANCER CENTER
|
PA
|
$284,831
|
|
Ovarian Cancer
|
NCI
|
5R01CA095023-06
|
|
Inflammation and Ovarian Cancer
|
NESS, ROBERTA
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
PA
|
$473,730
|
|
Ovarian Cancer
|
NCI
|
5R01CA106298-05
|
|
Imbalancing DNA BER to enhance Ovarian Tumor Sensitivity
|
KELLEY, MARK
|
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
|
IN
|
$285,864
|
|
Ovarian Cancer
|
NCI
|
5R21CA128222-02
|
|
Infectivity Enhanced Virotherapy For Ovarian Cancer
|
ALVAREZ, RONALD
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
AL
|
$275,500
|
|
Ovarian Cancer
|
NCI
|
5R01CA112162-04
|
|
The role of complement in ovarian cancer
|
LAMBRIS, JOHN
|
UNIVERSITY OF PENNSYLVANIA
|
PA
|
$296,817
|
|
Ovarian Cancer
|
NCI
|
5R01CA113783-04
|
|
Development of tumor based antigen presenting cells
|
RILEY, JAMES
|
UNIVERSITY OF PENNSYLVANIA
|
PA
|
$262,249
|
|
Ovarian Cancer
|
NHGRI
|
5R01HG004064-02
|
|
Do Physicians Understand Uncertain Variants and Other Genetic Test Results?
|
PLON, SHARON
|
BAYLOR COLLEGE OF MEDICINE
|
TX
|
$331,088
|
|
Ovarian Cancer
|
NCI
|
5R01CA086061-08
|
|
Mechanistic Comparison of Cisplatin with Synthetic DNA Repair-Shielding Anticance
|
ESSIGMANN, JOHN
|
MASSACHUSETTS INSTITUTE OF TECHNOLOGY
|
MA
|
$282,619
|
|
Ovarian Cancer
|
NCI
|
5R01CA095071-07
|
|
Epithelial Positioning Organization and Ovarian Cancer
|
XU, XIANGXI MIKE
|
UNIVERSITY OF MIAMI SCHOOL OF MEDICINE
|
FL
|
$323,942
|
|
Ovarian Cancer
|
NCI
|
5R01CA121119-02
|
|
Autocrine Wnt signaling in human breast and ovarian cancer cells
|
BAFICO, ANNA
|
MOUNT SINAI SCHOOL OF MEDICINE OF NYU
|
NY
|
$322,050
|
|
Ovarian Cancer
|
NCI
|
5R01CA107506-04
|
|
Novel human gene-IG20-potential role in cancer therapy
|
PRABHAKAR, BELLUR
|
UNIVERSITY OF ILLINOIS AT CHICAGO
|
IL
|
$261,235
|
|
Ovarian Cancer
|
NCI
|
5R01CA112570-05
|
|
Progesterone-mediated protection against ovarian cancer
|
HO, SHUK-MEI
|
UNIVERSITY OF CINCINNATI
|
OH
|
$258,707
|
|
Ovarian Cancer
|
NCI
|
5R01CA120197-03
|
|
KALLIKREINS AS DIAGNOSTIC MARKERS OF OVARIAN CARCINOMA
|
DIAMANDIS, ELEFTHERIOS
|
MT SINAI HOSP-SAMUEL LUNENFELD RES INST
|
CANADA
|
$216,880
|
|
Ovarian Cancer
|
NCI
|
5R01CA115483-04
|
|
Therapeutic Targeting Agents for Ovarian Cancer
|
LAM, KIT
|
UNIVERSITY OF CALIFORNIA DAVIS
|
CA
|
$301,109
|
|
Ovarian Cancer
|
NCI
|
5K05CA096558-05
|
|
Psychological and Behavioral Impact of Cancer Screening
|
ANDRYKOWSKI, MICHAEL
|
UNIVERSITY OF KENTUCKY
|
KY
|
$128,411
|
|
Ovarian Cancer
|
NCI
|
5R01CA112354-04
|
|
Modeling ovarian carcinoma by defined genetic alterations
|
NIKITIN, ALEXANDER
|
CORNELL UNIVERSITY ITHACA
|
NY
|
$266,292
|
|
Ovarian Cancer
|
NCI
|
5R01CA112523-03
|
|
Steroid Hormone Genes and Ovarian Cancer Risk
|
ROSSING, MARY
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
WA
|
$782,880
|
|
Ovarian Cancer
|
NCI
|
5R21CA127837-02
|
|
Web-based Family History Screening for Hereditary Breast Cancer Risk
|
ACHESON, LOUISE
|
CASE WESTERN RESERVE UNIVERSITY
|
OH
|
$154,500
|
|
Ovarian Cancer
|
NCI
|
5R01CA120429-02
|
|
Regulation of MDR1 Expression and Drug Resistance by CD44
|
RODRIGUEZ-RODRIGUEZ, LORNA
|
UNIV OF MED/DENT NJ-R W JOHNSON MED SCH
|
NJ
|
$296,400
|
|
Ovarian Cancer
|
NCI
|
5R01CA099985-03
|
|
Human Tregs in Ovarian Cancer
|
ZOU, WEIPING
|
UNIVERSITY OF MICHIGAN AT ANN ARBOR
|
MI
|
$209,581
|
|
Ovarian Cancer
|
NCI
|
1K99CA133190-01
|
|
Epidermal growth factor regulation of miR-125a promotes invasive ovarian cancer
|
COWDEN DAHL, KAREN
|
UNIVERSITY OF NEW MEXICO
|
NM
|
$120,150
|
|
Ovarian Cancer
|
NCI
|
5R01CA124515-02
|
|
Vascular Leukocytes influence the tumor microenvironment
|
CONEJO-GARCIA, JOSE
|
DARTMOUTH COLLEGE
|
NH
|
$303,810
|
|
Ovarian Cancer
|
NCI
|
5R01CA125636-02
|
|
The Fanconi Anemia-BRCA Pathway And Chemosensitivity of Human Cancer
|
TANIGUCHI, TOSHIYASU
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
WA
|
$308,883
|
|
Ovarian Cancer
|
NCI
|
5R01CA123170-03
|
|
MUC-1 related cancer immunity: determinants and predictive significance
|
CRAMER, DANIEL
|
BRIGHAM AND WOMEN'S HOSPITAL
|
MA
|
$278,781
|
|
Ovarian Cancer
|
NCI
|
5R01CA108990-04
|
|
Multianalyte Assay For Early Diagnosis Of Ovarian Cancer
|
LOKSHIN, ANNA
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
PA
|
$517,492
|
|
Ovarian Cancer
|
NCI
|
5R01CA116984-02
|
|
G Proteins and Their Receptors in Tumor Cell Metastasis
|
DHANASEKARAN, DANNY
|
TEMPLE UNIVERSITY
|
PA
|
$302,815
|
|
Ovarian Cancer
|
NCI
|
5R01CA083821-09
|
|
Replicative adenoviruses with enhanced infectivity
|
CURIEL, DAVID
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
AL
|
$247,476
|
|
Ovarian Cancer
|
NCI
|
5R01CA047988-18
|
|
Women's Health Study: Continued Follow-up
|
BURING, JULIE
|
BRIGHAM AND WOMEN'S HOSPITAL
|
MA
|
$1,680,173
|
|
Ovarian Cancer
|
NCI
|
5R01CA115780-04
|
|
Diagnosis of Ovarian Cancer by Confocal Microendoscopy
|
GMITRO, ARTHUR
|
UNIVERSITY OF ARIZONA
|
AZ
|
$279,194
|
|
Ovarian Cancer
|
NCI
|
5R03CA126775-02
|
|
Symptom Measurement and Interrelationships During Chemotherapy for Ovarian Cancer
|
JIM, HEATHER
|
H. LEE MOFFITT CANCER CTR & RES INST
|
FL
|
$83,000
|
|
Ovarian Cancer
|
NCI
|
5R01CA017393-33
|
|
Mullerian Inhibiting Substance
|
DONAHOE, PATRICIA
|
MASSACHUSETTS GENERAL HOSPITAL
|
MA
|
$324,032
|
|
Ovarian Cancer
|
NCI
|
5R01CA110793-05
|
|
Tumor metastasis: Biobehavioral mechanisms
|
SOOD, ANIL
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
TX
|
$329,472
|
|
Ovarian Cancer
|
NCI
|
1R01CA123249-01A2
|
|
Regulation of Serine Protease HtrA1 and Chemoresponse
|
SHRIDHAR, VIJAYALAKSHMI
|
MAYO CLINIC COLL OF MEDICINE, ROCHESTER
|
MN
|
$305,050
|
|
Ovarian Cancer
|
NCI
|
5R01CA121187-02
|
|
Monitoring of advanced virotherapy for ovarian cancer
|
CURIEL, DAVID
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
AL
|
$275,500
|
|
Ovarian Cancer
|
NCI
|
5R01CA106878-04
|
|
Biomarkers with Biological Function in Ovarian Carcinoma
|
SKUBITZ, AMY
|
UNIVERSITY OF MINNESOTA TWIN CITIES
|
MN
|
$283,150
|
|
Ovarian Cancer
|
NCI
|
5R01CA092520-08
|
|
Tumor Host Range Mutants of Polyoma and Their Targets
|
BENJAMIN, THOMAS
|
HARVARD UNIVERSITY (MEDICAL SCHOOL)
|
MA
|
$617,981
|
|
Ovarian Cancer
|
NCI
|
1R01CA129080-01A1
|
|
The Roles of HBXAP Gene in Ovarian Cancer
|
SHIH, IE-MING
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$340,300
|
|
Ovarian Cancer
|
NCI
|
5F32CA125959-02
|
|
Analysis of BRCA1/non-coding RNA interactions
|
LU, SHIHUA
|
DANA-FARBER CANCER INSTITUTE
|
MA
|
$51,278
|
|
Ovarian Cancer
|
NCI
|
5R01CA114037-02
|
|
Taxane Resistance in Breast and Ovarian Cancer Cells
|
SIKIC, BRANIMIR
|
STANFORD UNIVERSITY
|
CA
|
$297,730
|
|
Ovarian Cancer
|
NCI
|
5R01CA118578-04
|
|
The Mechanism of BRCA1 in Tumor Suppression
|
HU, YANFEN
|
UNIVERSITY OF TEXAS HLTH SCI CTR SAN ANT
|
TX
|
$201,308
|
|
Ovarian Cancer
|
NCI
|
1R03CA133915-01
|
|
Dietary Intervention in the Gallus Domesticus Model of Ovarian Cancer
|
HALES, DALE
|
UNIVERSITY OF ILLINOIS AT CHICAGO
|
IL
|
$78,500
|
|
Ovarian Cancer
|
NCI
|
5K08CA106868-05
|
|
Role of Phapl in apoptosome regulation in ovarian cancer
|
LIU, J
|
UNIVERSITY OF MICHIGAN AT ANN ARBOR
|
MI
|
$138,510
|
|
Ovarian Cancer
|
NCI
|
5R01CA118158-03
|
|
The role of BRCA1 in nonhomologous repair of chromosomal double-strand breaks
|
XIA, FEN
|
VANDERBILT UNIVERSITY
|
TN
|
$238,105
|
|
Ovarian Cancer
|
NCI
|
5R01CA123088-02
|
|
Novel immunosupressive macrophages in human ovarian tumor
|
ZOU, WEIPING
|
UNIVERSITY OF MICHIGAN AT ANN ARBOR
|
MI
|
$288,800
|
|
Ovarian Cancer
|
NCI
|
2R01CA085289-05A1
|
|
DNA Methylation and Ovarian Cancer
|
NEPHEW, KENNETH
|
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
|
IN
|
$264,396
|
|
Ovarian Cancer
|
NCI
|
5R01CA122581-03
|
|
Tumor-Associated Antigens in Early Stage Serous Carcinoma
|
RODEN, RICHARD
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$304,849
|
|
Ovarian Cancer
|
NCI
|
5K25CA120350-02
|
|
A near-infrared contrast agent for targeted imaging of cancer
|
ROMANOWSKI, MAREK
|
UNIVERSITY OF ARIZONA
|
AZ
|
$134,083
|
|
Ovarian Cancer
|
NCI
|
5R01CA113891-03
|
|
BARD1 phosphorylation in breast and ovarian cancer
|
BAER, RICHARD
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
NY
|
$218,696
|
|
Ovarian Cancer
|
NCI
|
5R01CA118213-03
|
|
Pharmacokinetic strategies to optimize IP chemotherapy
|
BALTHASAR, JOSEPH
|
STATE UNIVERSITY OF NEW YORK AT BUFFALO
|
NY
|
$255,609
|
|
Ovarian Cancer
|
NCI
|
5R01CA119078-03
|
|
CELL NON-AUTONOMOUS MODE OF TUMOR SUPPRESSION BY BRCA1
|
DUBEAU, LOUIS
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
CA
|
$224,748
|
|
Ovarian Cancer
|
NCI
|
5R01CA094172-07
|
|
Molecular Pathogenesis of Ovarian Endometrioid Adenocarcinomas
|
CHO, KATHLEEN
|
UNIVERSITY OF MICHIGAN AT ANN ARBOR
|
MI
|
$261,178
|
|
Ovarian Cancer
|
NCI
|
5R01CA109545-03
|
|
Receptor Cross-Talk in Early Metastatic Dissemination
|
STACK, MARY
|
UNIVERSITY OF MISSOURI-COLUMBIA
|
MO
|
$243,979
|
|
Ovarian Cancer
|
NCI
|
5R01CA075334-11
|
|
MRI studies of angiogenesis in ovarian cancer
|
NEEMAN, MICHAL
|
WEIZMANN INSTITUTE OF SCIENCE
|
ISRAEL
|
$102,771
|
|
Ovarian Cancer
|
NCI
|
5R01CA116779-03
|
|
Vascular Leukocytes Induce regulatory T cells (Treg) in Tumors
|
COUKOS, GEORGE
|
UNIVERSITY OF PENNSYLVANIA
|
PA
|
$271,456
|
|
Ovarian Cancer
|
NCI
|
5R01CA119388-04
|
|
Photodestruction of Ovarian Cancer: ErbB3 Targeted Aptamer Nanoparticle Conjugate
|
HASAN, TAYYABA
|
MASSACHUSETTS GENERAL HOSPITAL
|
MA
|
$475,527
|
|
Ovarian Cancer
|
NCI
|
2R44CA103177-02A1
|
|
Photodynamic Therapy of Disseminated Peritoneal Tumor Using New Photosensitizers
|
WHARTON, J
|
LYNNTECH, INC.
|
TX
|
$608,725
|
|
Ovarian Cancer
|
NCI
|
5R01CA106414-04
|
|
Population-Based Analysis of Ovarian Cancer Biomarkers
|
SUTPHEN, REBECCA
|
H. LEE MOFFITT CANCER CTR & RES INST
|
FL
|
$576,087
|
|
Ovarian Cancer
|
NCI
|
1R41CA126011-01A2
|
|
PARP Inhibitor Targeted Therapy for Breast Cancer
|
HOLT, JEFFREY
|
TISSUE GENETICS, INC.
|
CO
|
$149,043
|
|
Ovarian Cancer
|
NCI
|
5U01CA111273-04
|
|
Affinity-based Seurm Proteomics: Breast/Ovarian Cancer
|
MCINTOSH, MARTIN
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
WA
|
$658,549
|
|
Ovarian Cancer
|
NIGMS
|
1F32GM084587-01
|
|
Mechanism of homology search in homologous recombination by Rad51 and Rad54.
|
MOSES, DANA
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
NY
|
$44,846
|
|
Ovarian Cancer
|
NCI
|
5R01CA118678-02
|
|
Apoptotic regulators in ovarian cancer
|
MOR, GIL
|
YALE UNIVERSITY
|
CT
|
$314,450
|
|
Ovarian Cancer
|
NCI
|
5K25CA128666-02
|
|
Comparative Proteomics Applied to the Avian Model of Ovarian Cancer
|
HAWKRIDGE, ADAM
|
NORTH CAROLINA STATE UNIVERSITY RALEIGH
|
NC
|
$143,370
|
|
Ovarian Cancer
|
NCI
|
5R01CA122443-02
|
|
Genetic Variation in the NF-kappaB Pathway and Ovarian Cancer Etiology
|
GOODE, ELLEN
|
MAYO CLINIC COLL OF MEDICINE, ROCHESTER
|
MN
|
$548,865
|
|
Ovarian Cancer
|
NIGMS
|
5F31GM078742-02
|
|
Role of estrogen and its receptors in ovarian cancer of the hen
|
TREVINO, LINDSEY
|
CORNELL UNIVERSITY ITHACA
|
NY
|
$37,452
|
|
Ovarian Cancer
|
NCI
|
5R03CA123621-02
|
|
c-Met Mediated Ovarian Cancer Cell Motility
|
LO, CHUN-MIN
|
UNIVERSITY OF SOUTH FLORIDA
|
FL
|
$72,500
|
|
Ovarian Cancer
|
NCI
|
5R01CA120061-04
|
|
Hormone levels during pregnancy and maternal ovarian cancer
|
LUKANOVA, ANNEKATRIN
|
GERMAN CANCER RESEARCH CENTER
|
GERM
|
$386,251
|
|
Ovarian Cancer
|
NCI
|
5R03CA125766-02
|
|
Methods for Statistical Analysis of Cancer Genetic Network Studies
|
FINKELSTEIN, DIANNE
|
MASSACHUSETTS GENERAL HOSPITAL
|
MA
|
$87,500
|
|
Ovarian Cancer
|
NCI
|
7K01CA115593-04
|
|
The Role of X-linked Gene Expression in Mammary Tumorigenesis
|
HUYNH, KHANH
|
UNIVERSITY OF MINNESOTA TWIN CITIES
|
MN
|
$111,660
|
|
Ovarian Cancer
|
NCI
|
5K24CA087933-08
|
|
Clinical Investigator Development in Solid Tumor Oncology
|
SPRIGGS, DAVID
|
SLOAN-KETTERING INSTITUTE FOR CANCER RES
|
NY
|
$153,090
|
|
Ovarian Cancer
|
NCI
|
5R01CA105207-04
|
|
Plasmacytoid dendritic cell behavior in ovarian cancer
|
CURIEL, TYLER
|
UNIVERSITY OF TEXAS HLTH SCI CTR SAN ANT
|
TX
|
$273,408
|
|
Ovarian Cancer
|
NCI
|
5R01CA118846-02
|
|
Regulation of gene silencing by exogenous sphingosine
|
SCHMELZ, EVA
|
VIRGINIA POLYTECHNIC INST AND ST UNIV
|
VA
|
$271,035
|
|
Ovarian Cancer
|
NCI
|
5F31CA123637-03
|
|
Ovarian Cancer Biomarker Discovery using scFv Arrays
|
RAMIREZ, ARTURO
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
WA
|
$33,009
|
|
Ovarian Cancer
|
NCI
|
5K07CA108987-03
|
|
Clinical Relevance of Mismatch Repair in Ovarian Cancer
|
PAL, TUYA
|
H. LEE MOFFITT CANCER CTR & RES INST
|
FL
|
$132,823
|
|
Ovarian Cancer
|
NCI
|
5R01CA086984-09
|
|
Regulation of Ovarian Carcinoma Proteinases
|
STACK, MARY
|
UNIVERSITY OF MISSOURI-COLUMBIA
|
MO
|
$223,262
|
|
Ovarian Cancer
|
NCI
|
5K22CA121991-02
|
|
Growth Inhibition Induced by Mifepristone in Ovarian Cancer
|
TELLERIA, CARLOS
|
UNIVERSITY OF SOUTH DAKOTA
|
SD
|
$138,745
|
|
Ovarian Cancer
|
NCI
|
5R01CA083855-09
|
|
Prophytactic surgery in carriers of BRCA 1/2 mutations
|
REBBECK, TIMOTHY
|
UNIVERSITY OF PENNSYLVANIA
|
PA
|
$714,168
|
|
Ovarian Cancer
|
NHLBI
|
5R01HL090559-02
|
|
Bayesian Modeling and Optimal Design for Studies of Gene-Environment Association
|
IVERSEN, EDWIN
|
DUKE UNIVERSITY
|
NC
|
$308,524
|
|
Ovarian Cancer
|
NCI
|
5K25CA111636-05
|
|
Clinico-Genomics for Improved Ovarian Cancer Treatment
|
CLARKE, JENNIFER
|
UNIVERSITY OF MIAMI SCHOOL OF MEDICINE
|
FL
|
$133,950
|
|
Ovarian Cancer
|
NCI
|
5R21CA124688-02
|
|
p53 signatures and pelvic serous carcinoma
|
CRUM, CHRISTOPHER
|
BRIGHAM AND WOMEN'S HOSPITAL
|
MA
|
$143,004
|
|
Ovarian Cancer
|
RMAP
|
5R01CA132630-02
|
|
Chemical Probes for Metabolic Pathway Discovery in Human Disease
|
CRAVATT, BENJAMIN
|
SCRIPPS RESEARCH INSTITUTE
|
CA
|
$602,495
|
|
Ovarian Cancer
|
NCI
|
5R03CA132155-02
|
|
Cancer Risks in Multi-ethnic Carriers of Unclassified BRCA1 Variants
|
WHITTEMORE, ALICE
|
STANFORD UNIVERSITY
|
CA
|
$79,000
|
|
Ovarian Cancer
|
NCI
|
5R01CA127562-02
|
|
Development of PEA 15 as a Targeted Therapeutic Gene for Ovarian Cancer
|
UENO, NAOTO
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
TX
|
$292,600
|
|
Ovarian Cancer
|
NCI
|
5F32CA123651-03
|
|
Liposomal Delivery of High LET Emitters to Cell Nuclei
|
HAR-EL, YAH-EL
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$50,428
|
|
Ovarian Cancer
|
NCI
|
5R01CA092889-07
|
|
Role of TGFbeta in Microtubule Dynamics
|
MULDER, KATHLEEN
|
PENNSYLVANIA STATE UNIV HERSHEY MED CTR
|
PA
|
$259,572
|
|
Ovarian Cancer
|
NICHD
|
5K12HD055881-02
|
|
VCU Building Interdisciplinary Research Careers in Women's Health
|
STRAUSS, JEROME
|
VIRGINIA COMMONWEALTH UNIVERSITY
|
VA
|
$50,000
|
|
Ovarian Cancer
|
OD
|
5K12HD055881-02
|
|
VCU Building Interdisciplinary Research Careers in Women's Health
|
STRAUSS, JEROME
|
VIRGINIA COMMONWEALTH UNIVERSITY
|
VA
|
$446,801
|
|
Ovarian Cancer
|
NCI
|
1R01CA134487-01
|
|
Mesothelin as biomarker and therapeutic target
|
HELLSTROM, INGEGERD
|
UNIVERSITY OF WASHINGTON
|
WA
|
$270,000
|
|
Ovarian Cancer
|
NCCAM
|
5R21AT004085-02
|
|
Therapeutic Efficacy of Flax Seed in the Prevention of Ovarian Cancer
|
HALES, DALE
|
UNIVERSITY OF ILLINOIS AT CHICAGO
|
IL
|
$191,568
|
|
Ovarian Cancer
|
OD
|
1R21CA134960-01
|
|
Novel Ovarian Cancer Detection Agents from Phage Display
|
DEUTSCHER, SUSAN
|
UNIVERSITY OF MISSOURI-COLUMBIA
|
MO
|
$184,400
|
|
Ovarian Cancer
|
NIA
|
1R03AG032602-01
|
|
Prophylactic oophorectomy: practice patterns & outcomes
|
CHAN, JOHN
|
UNIVERSITY OF CALIFORNIA SAN FRANCISCO
|
CA
|
$77,152
|
|
Ovarian Cancer
|
NCI
|
1R01CA135312-01
|
|
Dendritic nanomedicine for cancer imaging and treatment
|
TUNG, CHING-HSUAN
|
METHODIST HOSPITAL RESEARCH INSTITUTE
|
TX
|
$294,650
|
|
Ovarian Cancer
|
NCI
|
1R01CA130911-01A1
|
|
Chimeric NKG2D receptors in ovarian cancer immunotherapy
|
SENTMAN, CHARLES
|
DARTMOUTH COLLEGE
|
NH
|
$331,793
|
|
Ovarian Cancer
|
NCI
|
1R01CA127913-01A2
|
|
MyD88-bearing tumors in immune-regulation and chemo-resistance
|
MOR, GIL
|
YALE UNIVERSITY
|
CT
|
$343,413
|
|
Ovarian Cancer
|
NCI
|
1R21CA133877-01A1
|
|
A Low-Dose Decitabine Strategy for Restoring Ovarian Cancer Sensitivity
|
MATEI, DANIELA
|
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
|
IN
|
$341,397
|
|
Ovarian Cancer
|
NCI
|
1R21CA132016-01A1
|
|
Evaluation of hGBP-1 as a marker for paclitaxel resistance in ovarian cancer
|
VESTAL, DEBORAH
|
UNIVERSITY OF TOLEDO
|
OH
|
$194,400
|
|
Ovarian Cancer
|
NCI
|
1K07CA131094-01A1
|
|
Epigentics and Female Reproductive Cancers
|
PERRIN, MARY
|
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
|
NY
|
$139,320
|
|
Ovarian Cancer
|
NCI
|
1R21CA116585-01A1
|
|
Inflammatory Markers in Circulation and Ovarian Cancer Risk
|
ARSLAN, ALAN
|
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
|
NY
|
$190,688
|
|
Ovarian Cancer
|
NHGRI
|
1R03HG004528-01A1
|
|
Attitudes Regarding Prenatal and Preimplantation Genetic Diagnosis For Inherited
|
RUBIN, LISA
|
NEW SCHOOL UNIVERSITY
|
NY
|
$75,000
|
|
Ovarian Cancer
|
NCI
|
1R01CA131183-01A2
|
|
RAS Signaling, Senescent Fibroblasts, and Ovarian Cancer Progression
|
LIU, JINSONG
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
TX
|
$255,640
|
|
Ovarian Cancer
|
NCI
|
1R41CA128145-01A2
|
|
OVARIAN CANCER PROTEOME VIA TISSUE MICRODISSECTION AND GEMINI TECHNOLOGIES
|
SAXENA, SATYA
|
CALIBRANT BIOSYSTEMS, INC.
|
MD
|
$253,782
|
|
Ovarian Cancer
|
NCI
|
1R03CA132573-01A1
|
|
Inflammatory Processes and Depression in a Syngeneic Model of Ovarian Cancer
|
LAMKIN, DONALD
|
UNIVERSITY OF IOWA
|
IA
|
$75,000
|
|
Ovarian Cancer
|
NCI
|
1R03CA136019-01
|
|
Prolactin as a risk biomarker of ovarian cancer
|
LOKSHIN, ANNA
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
PA
|
$75,750
|
|
Ovarian Cancer
|
NCI
|
1F32CA136152-01
|
|
Targeted Photoactivated Nanoparticles for the Treatment of Ovarian Cancer
|
NEUMAN, DANIEL
|
MASSACHUSETTS GENERAL HOSPITAL
|
MA
|
$46,826
|
|
Ovarian Cancer
|
NINR
|
1R01NR010735-01A1
|
|
Web-Based Ovarian Cancer Symptom Control: Nurse-Guided vs. Self-Directed
|
DONOVAN, HEIDI
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
PA
|
$579,255
|
|
Ovarian Cancer
|
NCI
|
2R01CA095319-06A2
|
|
Novel Fas/CD95 Signaling Mechanisms
|
PETER, MARCUS
|
UNIVERSITY OF CHICAGO
|
IL
|
$275,709
|
|
Ovarian Cancer
|
NCCAM
|
3U19AT002022-03S1
|
|
NESA Acupuncture Research Collaborative
|
WAYNE, PETER
|
NEW ENGLAND SCHOOL OF ACUPUNCTURE
|
MA
|
$678,327
|
|
Ovarian Cancer
|
NCI
|
5U19CA113341-04
|
0002
|
OVARIAN CANCER MESOTHELIN ANIMAL MODEL/DNA VACCINES
|
WU, T.-C.
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$234,484
|
|
Ovarian Cancer
|
NCI
|
5U19CA113341-04
|
0003
|
EVALUATE LAG3 AND OTHER IMMUNE MODULATORS
|
PARDOLL, DREW
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$232,011
|
|
Ovarian Cancer
|
NCI
|
5U19CA113341-04
|
0004
|
EVALUATE B7H1/H4 IN MOUSE MODELS AND IN HUMAN PRE-CLINICAL STUDIES
|
CHEN, LIEPING
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$234,896
|
|
Ovarian Cancer
|
NHGRI
|
1R01HG005055-01
|
|
INTERNET INTERVENTION FOR BRCA1/BRCA2 UNINFORMATIVES
|
SCHWARTZ, MARC
|
GEORGETOWN UNIVERSITY
|
DC
|
$751,312
|
|
Ovarian Cancer
|
NCI
|
5P01CA077839-10
|
0008
|
COX-1 as a Target for Ovarian Cancer Prevention and Treatment
|
DEY, SUDHANSU
|
VANDERBILT UNIVERSITY
|
TN
|
$184,787
|
|
Ovarian Cancer
|
NCI
|
5P30CA015083-34
|
9020
|
CORE-- Protocol-Specific Research Support
|
ADJEI, ALEX
|
MAYO CLINIC COLL OF MEDICINE, ROCHESTER
|
MN
|
$236,631
|
|
Ovarian Cancer
|
NCI
|
2U54CA096297-06A1
|
0008
|
Synthesis and Pre-Clinical Evaluation of Targeted, Iron-Based MRI Contrast Agents
|
RAPTIS, RAPHAEL
|
UNIVERSITY OF PUERTO RICO
|
PR
|
$88,939
|
|
Ovarian Cancer
|
NCI
|
3R01CA115483-04S1
|
|
Therapeutic Targeting Agents for Ovarian Cancer
|
LAM, KIT
|
UNIVERSITY OF CALIFORNIA DAVIS
|
CA
|
$59,963
|
|
Ovarian Cancer
|
NCI
|
5P01CA087969-09
|
0007
|
HORMONES, DIET AND RISK OF OVARIAN CANCER
|
HANKINSON, SUSAN
|
BRIGHAM AND WOMEN'S HOSPITAL
|
MA
|
$234,582
|
|
Ovarian Cancer
|
NCI
|
5P01CA087969-09
|
0008
|
STATISTICAL INNOVATIONS IN RISK MODELING
|
ROSNER, BERNARD
|
BRIGHAM AND WOMEN'S HOSPITAL
|
MA
|
$152,114
|
|
Ovarian Cancer
|
NCI
|
3R01CA086984-09S1
|
|
Regulation of Ovarian Carcinoma Proteinases
|
STACK, MARY
|
UNIVERSITY OF MISSOURI-COLUMBIA
|
MO
|
$48,237
|
|
Ovarian Cancer
|
NCI
|
5P01CA052477-16
|
0006
|
The Molecular Genetics of MUC16
|
BOYD, JEFF
|
SLOAN-KETTERING INSTITUTE FOR CANCER RES
|
NY
|
$421,486
|
|
Ovarian Cancer
|
NCI
|
5P01CA052477-16
|
0007
|
Development of Antibody and T-Cell Inducing Vaccines
|
LIVINGSTON, PHILIP
|
SLOAN-KETTERING INSTITUTE FOR CANCER RES
|
NY
|
$642,726
|
|
Ovarian Cancer
|
NCI
|
5P01CA052477-16
|
0008
|
Cellular Immunity Targeting Epithelial Ovarian Cancer
|
O'REILLY, RICHARD
|
SLOAN-KETTERING INSTITUTE FOR CANCER RES
|
NY
|
$352,723
|
|
Ovarian Cancer
|
NCI
|
5P01CA052477-16
|
0009
|
Novel Strategy for the Re-Induction & Consolidation of Remission in Ovary Cancer
|
SPRIGGS, DAVID
|
SLOAN-KETTERING INSTITUTE FOR CANCER RES
|
NY
|
$231,061
|
|
Ovarian Cancer
|
NCI
|
5P01CA052477-16
|
9002
|
Core--Biostatistics
|
THALER, HOWARD
|
SLOAN-KETTERING INSTITUTE FOR CANCER RES
|
NY
|
$223,981
|
|
Ovarian Cancer
|
NCI
|
5P01CA052477-16
|
9003
|
Core--Pathology
|
SOSLOW, ROBERT
|
SLOAN-KETTERING INSTITUTE FOR CANCER RES
|
NY
|
$165,319
|
|
Ovarian Cancer
|
NCI
|
5P50CA083636-10
|
0001
|
Molecular Targets for Prognosis and Therapy
|
HOOD, LEROY
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
WA
|
$567,737
|
|
Ovarian Cancer
|
NCI
|
5P50CA083636-10
|
0004
|
Biomarkers for Ovarian Cancer Diagnosis and Screening
|
MCINTOSH, MARTIN
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
WA
|
$143,018
|
|
Ovarian Cancer
|
NCI
|
5P50CA083636-10
|
0006
|
Adoptive T Cell Therapy of Ovarian Cancer
|
YEE, CASSIAN
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
WA
|
$286,393
|
|
Ovarian Cancer
|
NCI
|
5P50CA083636-10
|
9001
|
Core--Leadership
|
URBAN, NICOLE
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
WA
|
$161,169
|
|
Ovarian Cancer
|
NCI
|
5P50CA083636-10
|
9002
|
Core--Clinical
|
DRESCHER, CHARLES
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
WA
|
$251,362
|
|
Ovarian Cancer
|
NCI
|
5P50CA083636-10
|
9003
|
Core--Specimen
|
KIVIAT, NANCY
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
WA
|
$531,317
|
|
Ovarian Cancer
|
NCI
|
N02CN63300-3-0-4
|
|
Computer Support for Ovarian Cancer Screening in PLCO Cancer Screening Trials
|
NO PI IDENTIFIED
|
INFORMATION MANAGEMENT SERVICES, INC.
|
MD
|
$283,111
|
|
Ovarian Cancer
|
NCI
|
5P30CA006927-46
|
9036
|
CORE--TRANSGENIC MOUSE
|
YOUNG, ROBERT
|
FOX CHASE CANCER CENTER
|
PA
|
$153,052
|
|
Ovarian Cancer
|
NIGMS
|
3R01GM052418-09S1
|
|
Mass Spectrometry Studies on Radical Reactions of DNA
|
KENTTAMAA, HILKKA
|
PURDUE UNIVERSITY WEST LAFAYETTE
|
IN
|
$24,527
|
|
Ovarian Cancer
|
NCI
|
N1CN25524A-73-0-1
|
|
Prostate, Lung, Colorectal and Ovarian (PLCO) Screening Trial
|
NO PI IDENTIFIED
|
UNIVERSITY OF UTAH
|
UT
|
$575,720
|
|
Ovarian Cancer
|
NCI
|
N1CN25522A-91-0-1
|
|
Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial
|
NO PI IDENTIFIED
|
GEORGETOWN UNIVERSITY
|
DC
|
$690,195
|
|
Ovarian Cancer
|
NCI
|
N1CN25518A-88-0-1
|
|
Prostate, Lung, Colorectal and Ovarian (PLCO) Screening Trial
|
NO PI IDENTIFIED
|
MARSHFIELD CLINIC RESEARCH FOUNDATION
|
WI
|
$677,003
|
|
Ovarian Cancer
|
NCI
|
N1CN25516A-90-0-1
|
|
Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial
|
NO PI IDENTIFIED
|
|
|
$441,068
|
|
Ovarian Cancer
|
NCI
|
N1CN25515A-83-0-1
|
|
Prostate, Lung, Colorectal and Ovarian (PLCO) Screening Trial
|
NO PI IDENTIFIED
|
PACIFIC HEALTH RESEARCH INSTITUTE
|
HI
|
$1,087,832
|
|
Ovarian Cancer
|
NCI
|
N1CN25514A-77-0-1
|
|
Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial
|
NO PI IDENTIFIED
|
|
|
$642,088
|
|
Ovarian Cancer
|
NCI
|
N1CN25513A-89-0-1
|
|
Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial
|
NO PI IDENTIFIED
|
UNIVERSITY OF MINNESOTA TWIN CITIES
|
MN
|
$1,371,201
|
|
Ovarian Cancer
|
NCI
|
N1CN25512A-100-0-1
|
|
Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial
|
NO PI IDENTIFIED
|
HENRY FORD HEALTH SYSTEM
|
MI
|
$892,391
|
|
Ovarian Cancer
|
NCI
|
N1CN25476A-75-0-1
|
|
Prostate, Lung, Colorectal and Ovarian (PLCO) Screening Trial
|
NO PI IDENTIFIED
|
WESTAT, INC.
|
MD
|
$2,685,388
|
|
Ovarian Cancer
|
NCI
|
5P01CA078039-09
|
0002
|
Molecular Pharmacology & Biochemistry of Dual Specificity Phosphatase Inhibitors
|
LAZO, JOHN
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
PA
|
$276,044
|
|
Ovarian Cancer
|
NCI
|
5P01CA017054-30
|
0001
|
Hormone Therapy and Risk of Ovarian Cancer
|
WU, ANNA
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
CA
|
$403,783
|
|
Ovarian Cancer
|
NCI
|
4R33CA110499-02
|
|
Molecular Profiling to Predict Response to Chemotherapy
|
LANCASTER, JOHNATHAN
|
H. LEE MOFFITT CANCER CTR & RES INST
|
FL
|
$322,613
|
|
Ovarian Cancer
|
NCI
|
5P50CA083638-10
|
0003
|
AKT as a Biomarker of Ovarian Cancer Progression and a Target for Therapy
|
TESTA, JOSEPH
|
FOX CHASE CANCER CENTER
|
PA
|
$799,787
|
|
Ovarian Cancer
|
NCI
|
5P50CA083638-10
|
0010
|
Mechanism of Cox-2 Inhibition in Ovarian Cancer Prevention
|
XU, XIANGXI MIKE
|
FOX CHASE CANCER CENTER
|
PA
|
$603,663
|
|
Ovarian Cancer
|
NCI
|
5P50CA083638-10
|
0011
|
Anti-Mullerian Inhibiting Substance Type II Receptor (MISIIR) Immunoconjugates to
|
ADAMS, GREGORY
|
FOX CHASE CANCER CENTER
|
PA
|
$733,901
|
|
Ovarian Cancer
|
NCI
|
5P01CA129186-02
|
0002
|
HOMOLOGY- DEPENDENT DNA REPAIR, HYPOXIA, AND CANCER THERAPY
|
GLAZER, PETER
|
YALE UNIVERSITY
|
CT
|
$302,309
|
|
Ovarian Cancer
|
NCI
|
N44CN73301-3-0-1
|
|
Biomarker Screening with Revoluntionary Neoabs
|
NO PI IDENTIFIED
|
NEOCLONE BIOTECHNOLOGY INTERNATIONAL
|
WI
|
$206,777
|
|
Ovarian Cancer
|
NCI
|
5U54CA113001-05
|
0003
|
Chromatin Landscaping of TGF-P/SMAD Signaling Targets
|
SALTZ, JOEL
|
OHIO STATE UNIVERSITY
|
OH
|
$249,546
|
|
Ovarian Cancer
|
NCI
|
5U54CA113001-05
|
0004
|
Predicting Drug Resistance in Cancer Genomes by DMA Methylation Profiling
|
NEPHEW, KENNETH
|
INDIANA UNIVERSITY
|
IN
|
$396,106
|
|
Ovarian Cancer
|
NCI
|
N1CN25511A-83-0-1
|
|
Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial
|
NO PI IDENTIFIED
|
|
|
$669,636
|
|
Ovarian Cancer
|
NIAID
|
5P01AI068730-02
|
0005
|
COMPLEMENT IN CANCER ESTABLISHMENT AND GROWTH
|
COUKOS, GEORGE
|
UNIVERSITY OF PENNSYLVANIA
|
PA
|
$342,004
|
|
Ovarian Cancer
|
NCI
|
4R33CA122904-02
|
|
Identification of T Cell-Defined Antigens in Ovarian Cancer
|
YEE, CASSIAN
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
WA
|
$391,435
|
|
Ovarian Cancer
|
NCI
|
5P50CA105009-05
|
0001
|
Modifiable Risk Factors and Gene/Environment interactions in Ovarian Cancer
|
HANKINSON, SUSAN
|
BRIGHAM AND WOMEN'S HOSPITAL
|
MA
|
$172,468
|
|
Ovarian Cancer
|
NCI
|
5P50CA105009-05
|
0002
|
Genetic Changes in Early Stage Ovarian Cancer
|
MOK, SAMUEL
|
BRIGHAM AND WOMEN'S HOSPITAL
|
MA
|
$222,918
|
|
Ovarian Cancer
|
NCI
|
5P50CA105009-05
|
0003
|
Identifying Novel Serum, Plasma, and Urine Biomarkers of Occult Ovarian Cancer
|
SKATES, STEVEN
|
MASSACHUSETTS GENERAL HOSPITAL
|
MA
|
$261,414
|
|
Ovarian Cancer
|
NCI
|
5P50CA105009-05
|
0004
|
Defining Clinical Response Genes in High-Risk Epithelial Ovarian Carcinoma
|
SEIDEN, MICHAEL
|
MASSACHUSETTS GENERAL HOSPITAL
|
MA
|
$296,575
|
|
Ovarian Cancer
|
NCI
|
5P50CA105009-05
|
0005
|
Novel Immunotherapeutic Approaches for Ovarian Cancer
|
KUFE, DONALD
|
BRIGHAM AND WOMEN'S HOSPITAL
|
MA
|
$303,237
|
|
Ovarian Cancer
|
NCI
|
5P50CA105009-05
|
9001
|
Core--Biostatistics
|
FINKELSTEIN, DIANNE
|
MASSACHUSETTS GENERAL HOSPITAL
|
MA
|
$355,802
|
|
Ovarian Cancer
|
NCI
|
5P50CA105009-05
|
9003
|
Developmental Research Program
|
SEIDEN, MICHAEL
|
MASSACHUSETTS GENERAL HOSPITAL
|
MA
|
$155,254
|
|
Ovarian Cancer
|
NCI
|
5P50CA105009-05
|
9004
|
Career Development Program
|
SEIDEN, MICHAEL
|
MASSACHUSETTS GENERAL HOSPITAL
|
MA
|
$155,255
|
|
Ovarian Cancer
|
NCI
|
7P01CA104177-04
|
0003
|
MDA-7/IL-24: Therapy of Ovarian Cancer
|
CURIEL, DAVID
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
NY
|
$332,546
|
|
Ovarian Cancer
|
NCI
|
7P01CA104177-04
|
9001
|
Core--Protein Purification
|
GUPTA, PANKAJ
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
NY
|
$112,665
|
|
Ovarian Cancer
|
NCI
|
7P01CA104177-04
|
9002
|
Core--Viral Vector
|
CURIEL, DAVID
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
NY
|
$107,756
|
|
Ovarian Cancer
|
NCI
|
3U01CA111273-04S1
|
|
Affinity-Based Serum Proteomics: Breast and Ovarian Can*
|
MCINTOSH, MARTIN
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
WA
|
$176,000
|
|
Ovarian Cancer
|
NCI
|
N1CN25404A-39-0-1
|
|
Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial - Lab
|
NO PI IDENTIFIED
|
|
|
$1,654,777
|
|
Ovarian Cancer
|
NCRR
|
5G12RR003032-24
|
5467
|
DISSECTING COX-1 RELATED GENE PATHWAYS IN OVARIAN CANCER
|
KHABELE, DINEO
|
MEHARRY MEDICAL COLLEGE
|
TN
|
$140,014
|
|
Ovarian Cancer
|
NCRR
|
5G12RR003037-24
|
5479
|
ROLES OF MSP58 IN NUCLEAR FUNCTION AND ONCOGENESIS
|
ZHONG, HUALIN
|
HUNTER COLLEGE
|
NY
|
$118,887
|
|
Ovarian Cancer
|
NCRR
|
5P51RR000163-49
|
6115
|
FEMALE ANDROGEN: METABOLIC SYNDROME, CARDIOVASCULAR DISEASE, OVARIAN CANCER
|
STOUFFER, RICHARD
|
OREGON HEALTH AND SCIENCE UNIVERSITY
|
OR
|
$54,119
|
|
Ovarian Cancer
|
NIA
|
5P51RR000163-49
|
6115
|
FEMALE ANDROGEN: METABOLIC SYNDROME, CARDIOVASCULAR DISEASE, OVARIAN CANCER
|
STOUFFER, RICHARD
|
OREGON HEALTH AND SCIENCE UNIVERSITY
|
OR
|
$1,393
|
|
Ovarian Cancer
|
NCRR
|
5P51RR000163-49
|
6146
|
BIOLOGY OF THE PRIMATE OVARIAN SURFACE EPITHELIUM
|
WRIGHT, JAY
|
OREGON HEALTH AND SCIENCE UNIVERSITY
|
OR
|
$54,119
|
|
Ovarian Cancer
|
NIA
|
5P51RR000163-49
|
6146
|
BIOLOGY OF THE PRIMATE OVARIAN SURFACE EPITHELIUM
|
WRIGHT, JAY
|
OREGON HEALTH AND SCIENCE UNIVERSITY
|
OR
|
$1,393
|
|
Ovarian Cancer
|
NCRR
|
5P51RR000163-49
|
6147
|
ESTROGEN-MEDIATED CELL CYCLE ARREST VIA P53 AND P21
|
WRIGHT, JAY
|
OREGON HEALTH AND SCIENCE UNIVERSITY
|
OR
|
$27,009
|
|
Ovarian Cancer
|
NIA
|
5P51RR000163-49
|
6147
|
ESTROGEN-MEDIATED CELL CYCLE ARREST VIA P53 AND P21
|
WRIGHT, JAY
|
OREGON HEALTH AND SCIENCE UNIVERSITY
|
OR
|
$695
|
|
Ovarian Cancer
|
NCRR
|
3P51RR000163-49S1
|
6635
|
SUPPORT FOR NATIONAL PRIMATE RESEARCH CENTER
|
SMITH, M
|
OREGON HEALTH AND SCIENCE UNIVERSITY
|
OR
|
$320,000
|
|
Ovarian Cancer
|
NCRR
|
2M01RR000043-48
|
6788
|
CLINICAL TRIAL: A PHASE II, OPEN-LABEL, NON-COMPARATIVE, INTERNATIONAL, MULTICEN
|
WEITZEL, JEFFREY
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
CA
|
$4,806
|
|
Ovarian Cancer
|
NCRR
|
2M01RR000043-48
|
6813
|
PHASE I TRIAL OF INTRAVENOUS FENRETINIDE (4-HPR) FOR PATIENTS WITH HEMATOLOGI
|
MOHRBACHER, ANN
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
CA
|
$155,024
|
|
Ovarian Cancer
|
NCRR
|
5M01RR000425-39
|
7339
|
BLOOD AND TISSUE BANKING IN GYNECOLOGICAL MALIGNANCIES
|
KARLAN, BETH
|
LA BIOMED RES INST/ HARBOR UCLA MED CTR
|
CA
|
$2,193
|
|
Ovarian Cancer
|
NCRR
|
5M01RR000188-44
|
7794
|
THE MOLECULAR BASIS OF FAMILIAL CANCER PREDISPOSITION SYNDROMES
|
PLON, SHARON
|
BAYLOR COLLEGE OF MEDICINE
|
TX
|
$1,785
|
|
Ovarian Cancer
|
NCRR
|
5M01RR000070-46
|
8028
|
CLINICAL TRIAL: OVARIAN CANCER PATIENTS WITH RECURRENT SYMPTOMATIC MALIGNANT ASC
|
BERAK, JONATHAN
|
STANFORD UNIVERSITY
|
CA
|
$1,138
|
|
Ovarian Cancer
|
NCRR
|
5M01RR000070-46
|
8029
|
CLINICAL TRIAL: ADVANCED EPITHELIAL OVARIAN CANCER AFTER A COMPLETE RESPONSE TO
|
BERAK, JONATHAN
|
STANFORD UNIVERSITY
|
CA
|
$341
|
|
Ovarian Cancer
|
NCRR
|
5M01RR000071-45
|
8308
|
SURGERY, PSYCHOLOGICAL FACTORS, BLOOD CLOTTING FACTORS IN WOMEN GYN PROCEDURES
|
HIGGINS, SARA
|
MOUNT SINAI SCHOOL OF MEDICINE OF NYU
|
NY
|
$1,142
|
|
Ovarian Cancer
|
NCRR
|
5M01RR000096-47
|
8501
|
CANCER SCREENING AND PREVENTION PROJECT FOR HIGH RISK WOMEN
|
MUGGIA, FRANCO
|
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
|
NY
|
$16,654
|
|
Ovarian Cancer
|
NCRR
|
5M01RR000096-47
|
8512
|
CLINICAL TRIAL: OSI 774 WITH CARBOPLATIN AND PACLITAXEL IN OVARIAN OR PERITONEAL
|
BLANK, SALLY
|
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
|
NY
|
$948
|
|
Ovarian Cancer
|
NCRR
|
5M01RR000096-47
|
8515
|
GOG-0199: USING SALPINGO-OOPHORECTOMY AND CA-125 TO SCREEN FOR OVARIAN CANCER
|
BLANK, SALLY
|
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
|
NY
|
$406
|
|
Ovarian Cancer
|
NCRR
|
5M01RR000096-47
|
8569
|
CLINICAL TRIAL: PACLITAXEL WITH GLEEVEC IN TAXANE-PRETREATED OVARIAN CANCER
|
MUGGIA, FRANCO
|
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
|
NY
|
$677
|
|
Ovarian Cancer
|
NCRR
|
5M01RR000096-47
|
8573
|
CLINICAL TRIAL: OXALIPLATIN PLUS TOPOTECAN FOR PATIENTS WITH PREVIOUSLY TREATED
|
TIERSTEN, AMY
|
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
|
NY
|
$2,708
|
|
Ovarian Cancer
|
NCRR
|
5M01RR000064-44
|
8598
|
OVARIAN CANCER SCREENING STUDY
|
BUYS, SAUNDRA
|
UNIVERSITY OF UTAH
|
UT
|
$3,525
|
|
Ovarian Cancer
|
NCRR
|
5M01RR000847-35
|
8675
|
SYNTHETIC PEPTIDES IN ADJUVANT VACCINATION IN OVARIAN, PERITONEAL, FALLOPIAN CA
|
JAZAERI, AMIR
|
UNIVERSITY OF VIRGINIA CHARLOTTESVILLE
|
VA
|
$15,512
|
|
Ovarian Cancer
|
NCRR
|
5M01RR023942-02
|
5241
|
CANCER GENETICS NETWORK (CGN) OVARIAN SCREENING PILOT TRIAL IN HIGH RIS WOMEN
|
ISAACS, CLAUDINE
|
GEORGETOWN UNIVERSITY
|
DC
|
$21,403
|
|
Ovarian Cancer
|
NCI
|
5P01CA042745-22
|
0014
|
LIPOSOMES
|
DEWHIRST, MARK
|
DUKE UNIVERSITY
|
NC
|
$143,991
|
|
Ovarian Cancer
|
NCRR
|
5P20RR016479-08
|
6342
|
ANTI-OVARIAN CANCER PROPERTIES OF RU-486
|
TELLERIA, CARLOS
|
UNIVERSITY OF SOUTH DAKOTA
|
SD
|
$28,696
|
|
Ovarian Cancer
|
NCRR
|
5P20RR015578-09
|
6443
|
GONAD-SPECIFIC TRANSCRIPTION FACTORS
|
FREIMAN, RICHARD
|
BROWN UNIVERSITY
|
RI
|
$235,609
|
|
Ovarian Cancer
|
NCRR
|
5P20RR016477-08
|
6467
|
SIGNALING PATHWAYS IN APIGENIN-INHIBITING TUMOR GROWTH
|
CHEN, ALLAN
|
MARSHALL UNIVERSITY
|
WV
|
$164,796
|
|
Ovarian Cancer
|
NCRR
|
5P20RR016474-08
|
6647
|
VITAMIN E,OVARIAN CANCER AND FERTILITY
|
MURDOCH, WILLIAM
|
UNIVERSITY OF WYOMING
|
WY
|
$194,206
|
|
Ovarian Cancer
|
NCRR
|
5P41RR004050-20
|
8532
|
ANALYSIS OF EXOSOMES FROM CISPLATIN RESISTANT AND SENSITIVE OVARIAN CANCER
|
HOWELL, STEPHEN
|
UNIVERSITY OF CALIFORNIA SAN DIEGO
|
CA
|
$9,756
|
|
Ovarian Cancer
|
NCI
|
Y1CO8103-1-0-7
|
|
caBIG-ICR Software Development Support for TCGA-Ovarian Cancer
|
NO PI IDENTIFIED
|
|
|
$245,318
|
|
Ovarian Cancer
|
NCI
|
5P30CA006516-44
|
9035
|
Core - Rapdi Case Identification
|
MUELLER, NANCY
|
DANA-FARBER CANCER INSTITUTE
|
MA
|
$205,193
|
|
Ovarian Cancer
|
NCI
|
5P30CA014089-33
|
9001
|
Molecular and Cell Biology
|
LANDOLPH, JOSEPH
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
CA
|
$381,691
|
|
Ovarian Cancer
|
NCI
|
5P30CA014089-33
|
9005
|
Transgenic/Knockout Mouse Core Facility
|
MAXSON, ROBERT
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
CA
|
$222,143
|
|
Ovarian Cancer
|
NCI
|
5P30CA014236-34
|
0010
|
BREAST AND OVARIAN ONCOLOGY
|
LYERLY, HERBERT
|
DUKE UNIVERSITY
|
NC
|
$25,791
|
|
Ovarian Cancer
|
NCI
|
5P50CA083639-09
|
0007
|
Early Detection of Epithelial Ovarian Cancer
|
BAST, ROBERT
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
TX
|
$288,852
|
|
Ovarian Cancer
|
NCI
|
5P50CA083639-09
|
0008
|
Cell-specific Targeting of Ovarian Cancer Vasculature
|
SOOD, ANIL
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
TX
|
$186,960
|
|
Ovarian Cancer
|
NCI
|
5P50CA083639-09
|
0009
|
Development of E1A Gene Therapy in Ovarian Cancer
|
HUNG, MIEN-CHIE
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
TX
|
$147,397
|
|
Ovarian Cancer
|
NCI
|
5P50CA083639-09
|
0010
|
Targeting the PI3K Pathway in Ovarian Cancer
|
MILLS, GORDON
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
TX
|
$147,397
|
|
